Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nanobiotix (NBTX) to EUR 32 from EUR 23 and keeps a Buy rating on the shares after the company reported initial data from the Part 1 of the open-label Phase 2 CONVERGE study evaluating JNJ-1900 as an enhancer to radiotherapy in patients with stage 3 inoperable lung cancer at the annual conference of European Lung Cancer Congress. The firm is adjusting its model to reflect “the robust initial data” and its increased confidence in JNJ-1900, the analyst tells investors.